{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Han J"],"funding":["Foundation National Natural Science Foundation of China","CAMS Innovation Fund for Medical Sciences (CIFMS)","Chinese Pharmaceutical Association-Yiling Biomedical Innovation Fund"],"pagination":["5052-5070"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10297637"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["45(6)"],"pubmed_abstract":["Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. Silencing information regulator 1 (SIRT1) was demonstrated to modulate cholesterol and lipid metabolism in NAFLD. Here, a novel SIRT1 activator, E1231, was studied for its potential improvement effects on NAFLD. C57BL/6J mice were fed a high-fat and high-cholesterol diet (HFHC) for 40 weeks to create a NAFLD mouse model, and E1231 was administered by oral gavage (50 mg/kg body weight, once/day) for 4 weeks. Liver-related plasma biochemistry parameter tests, Oil Red O staining, and hematoxylin-eosin staining results showed that E1231 treatment ameliorated plasma dyslipidemia, plasma marker levels of liver damage (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), liver total cholesterol (TC"],"journal":["Current issues in molecular biology"],"pubmed_title":["SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism."],"pmcid":["PMC10297637"],"funding_grant_id":["CPA-B04-ZC-2021-005","2022-JKCS-10, 2021-1-I2M-030","81973328"],"pubmed_authors":["Lei L","Zhang J","Si S","Li Y","Li S","Zhang Y","Jiang X","Wang W","Han J","Liu C","Sheng R","Wu Y","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism.","description":"Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. Silencing information regulator 1 (SIRT1) was demonstrated to modulate cholesterol and lipid metabolism in NAFLD. Here, a novel SIRT1 activator, E1231, was studied for its potential improvement effects on NAFLD. C57BL/6J mice were fed a high-fat and high-cholesterol diet (HFHC) for 40 weeks to create a NAFLD mouse model, and E1231 was administered by oral gavage (50 mg/kg body weight, once/day) for 4 weeks. Liver-related plasma biochemistry parameter tests, Oil Red O staining, and hematoxylin-eosin staining results showed that E1231 treatment ameliorated plasma dyslipidemia, plasma marker levels of liver damage (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), liver total cholesterol (TC","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-26T04:54:51.521Z","creation":"2025-04-06T11:14:23.605Z"},"accession":"S-EPMC10297637","cross_references":{"pubmed":["37367070"],"doi":["10.3390/cimb45060321"]}}